HIV/AIDS Topics Truvada PrEP Demonstration Project Debuts in San Francisco
- Details
- Category: HIV Prevention
- Published on Friday, 28 September 2012 00:00
- Written by Liz Highleyman
The San Francisco Department of Public Health's new pre-exposure prophylaxis demonstration project opened for enrollment at City Clinic on Friday, September 21. Men who have sex with men (MSM) and transgender women with ongoing risk of HIV infection are eligible to receive Truvada PrEP for up to 1 year.
Pre-exposure prophylaxis, better known as PrEP, refers to use of antiretroviral drugs prior to unprotected sex or other exposures to prevent HIV from taking hold in the body. Most PrEP research has looked at an oral combination of tenofovir plus emtricitabine, the drugs in Truvada. Already a widely used component of HIV treatment, the U.S. Food and Drug Administration approved Truvada for PrEP on July 16, 2012.
SF Forum Reveals Conflicting Views about Serosorting to Reduce HIV Transmission Risk
- Details
- Category: HIV Prevention
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
Bay Area gay and bisexual men hold a wide spectrum of views about condom-free sex and serosorting, according to a well-attended community discussion last week. "Seroadaptive" practices are a popular sexual harm reduction approach, but due to lack of awareness about recent infection, it may actually be safer to have unprotected sex with an HIV positive partner on antiretroviral therapy (ART) with stable viral load suppression.
AIDS Vaccine Conference Underway in Boston, Researchers Report Progress and Challenges
- Details
- Category: HIV Vaccines
- Published on Tuesday, 11 September 2012 00:00
- Written by Press Release
AIDS Vaccine 2012, an annual conference focusing on HIV vaccine research, takes place this week in Boston. There have been several setbacks but also some promising advances in vaccine development over the past few years, and the meeting offers an opportunity to look at where the field has been and where it is going.
Analysis Confirms Link Between PrEP Adherence and Reduced HIV Risk, Estimates Effective Dosing
- Details
- Category: HIV Prevention
- Published on Thursday, 20 September 2012 00:00
- Written by NIAID
Investigators with the iPrEx study, which demonstrated that pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine (Truvada) can dramatically lower the risk of HIV infection among gay and bisexual men, have now provided estimates of adherence levels need to achieve a high degree of protection. While more complete adherence is best, men may be able to reduce their HIV risk by 90% if they take Truvada 4 times weekly, or about every other day. 
Coverage of the 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, September 9-12, 2012.
Topics highlighted this year include experimental antiretroviral drugs, complications related to HIV and its treatment, recent developments in hepatitis C therapy, cancer caused by HPV, influenza, tuberculosis, and STDs.
HIVandHepatitis.com ICAAC 2012 conference section
More Articles...
- Coverage of 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- AAP Says Infant Circumcision Benefit Outweighs Risk, but Doesn't Recommend for All
- CDC Issues PrEP Guidance for Prevention of Heterosexual HIV Transmission
- AIDS 2012: NIH to Test Dapivirine Vaginal Ring for HIV Prevention
Web Design and Development by